• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Non-Hodgkin’s Lymphoma - Articles and news items

predosing-red-bone-marrow

Predosing NHL patients with lilotomab before betalutin therapy lowers haematological toxicity

Industry news / 5 September 2016 / Niamh Louise Marriott, Digital Content Producer

RM radiation doses were significantly higher in the patients who did not receive predosing, indicating that pre-dosing with lilotomab has a protective…

Gazyvaro Roche

Blood cancer study yields disappointing results

Industry news / 19 July 2016 / Niamh Louise Marriott

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…

gazyva

Positive results from Phase III study of Gazyva in follicular lymphoma

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

Results from an interim analysis showed that Gazyva-based treatment significantly reduced the risk of disease worsening or death…

nhl treatment market

B-cell NHL treatment market to reach $5.45 billion by 2024, says GlobalData

Industry news / 28 January 2016 / Victoria White

GlobalData states that the limited growth in the B-cell NHL treatment market will be hindered by the entry of biosimilars and generics combined with a weak pipeline…

tazemetostat

Epizyme releases additional data from Phase 1 study of tazemetostat in non-Hodgkin’s lymphoma

Industry news / 22 June 2015 / Victoria White

Epizyme has reported results from the ongoing Phase 1 trial of tazemetostat in patients with advanced B-cell non-Hodgkin’s lymphoma and solid tumours…

roche-gazyvaro

Gazyvaro stalls growth and spread of indolent non-Hodgkin’s lymphoma

Industry news / 1 June 2015 / Victoria White

Results from a Phase III study show that Gazyvaro provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL)…

Non Hodgkin's Lymphoma

Global Non-Hodgkin Lymphoma therapeutics market value to hit $9.2 billion by 2020

Industry news / 29 October 2014 / GBI Research

The global Non-Hodgkin Lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 7.4%, says business intelligence provider GBI Research…

Non Hodgkin's Lymphoma

Non-Hodgkin’s Lymphoma drug market set to double to $8.4 billion by 2019

Industry news, News / 27 April 2011 / Decision Resources

Decision Resources suggests that growth will be driven by the launches of premium-priced therapies…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +